HBeAg阴性慢性乙肝停药成功相关病毒与免疫因素
本研究前瞻性纳入27例无肝硬化、病毒完全抑制超过3年的HBeAg阴性慢性乙肝患者,分析停药后病毒学与免疫学因素。中位随访34个月,82%患者维持停药,30%实现HBsAg清除;基线HBsAg≤1000 IU/ml及功能性HBV特异性CD8+ T细胞频率较高与停药成功相关。
要点
- 基线HBsAg≤1000 IU/ml与停药后HBsAg清除相关。
- 基线功能性HBV特异性CD8+ T细胞频率高与持续病毒控制相关。
- 肝内cccDNA转录水平降低与HBsAg清除相关。
核心结论
- cccDNA转录降低和低HBsAg水平与HBeAg阴性慢性乙肝患者停药后HBsAg清除相关。
- 基线功能性HBV特异性T细胞的存在与停药成功结局相关。
研究设计与样本
- 前瞻性研究纳入27例无肝硬化、病毒完全抑制超过3年的HBeAg阴性慢性乙肝患者。
- 基线定量肝内HBV-DNA、HBV-RNA和cccDNA,并纵向分析血清标志物和HBV特异性T细胞反应。
主要发现
- 中位随访34个月,22/27例(82%)维持停药,其中8例(占总数30%)HBsAg清除。
- 基线HBsAg与肝内HBV-DNA和HBV-RNA显著相关,且HBsAg清除者这些参数较低。
- 所有患者可检测到cccDNA水平相似,与临床结局无关。
- 实现功能性治愈者基线HBsAg水平≤1000 IU/ml。
- 基线功能性HBV特异性CD8+ T细胞频率增加与停药后持续病毒控制相关,停药后这些反应持续但未增加;CD4+ T细胞反应呈相似但无统计学意义的趋势。
关键数值与推荐
- 功能性治愈者基线HBsAg≤1000 IU/ml。
- 基线HBsAg与肝内HBV-DNA和HBV-RNA显著相关。
临床怎么用
- 对于无肝硬化的HBeAg阴性慢性乙肝患者,基线HBsAg≤1000 IU/ml和功能性HBV特异性T细胞频率较高可能提示停药后成功概率较高。
- 停药决策需综合病毒学和免疫学指标进行个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Factors associated with a successful outcome upon nucleos(t)ide analogue (NA) treatment withdrawal in HBeAg-negative chronic hepatitis B (CHB) patients have yet to be clarified. The objective of this study was to analyse the HBV-specific T cell response, in parallel with peripheral and intrahepatic viral parameters, in patients undergoing NA discontinuation. METHODS: Twenty-seven patients without cirrhosis with HBeAg-negative CHB with complete viral suppression (>3 years) were studied prospectively. Intrahepatic HBV-DNA (iHBV-DNA), intrahepatic HBV-RNA (iHBV-RNA), and covalently closed circular DNA (cccDNA) were quantified at baseline. Additionally, serum markers (HBV-DNA, HBsAg, HBV core-related antigen [HBcrAg] and HBV-RNA) and HBV-specific T cell responses were analysed at baseline and longitudinally throughout follow-up. RESULTS: After a median follow-up of 34 months, 22/27 patients (82%) remained off-therapy, of whom 8 patients (30% of the total cohort) lost HBsAg. Baseline HBsAg significantly correlated with iHBV-DNA and iHBV-RNA, and these parameters were lower in patients who lost HBsAg. All patients had similar levels of detectable cccDNA regardless of their clinical outcome. Patients achieving functional cure had baseline HBsAg levels ≤1,000 IU/ml. Similarly, an increased frequency of functional HBV-specific CD8+ T cells at baseline was associated with sustained viral control off treatment. These HBV-specific T cell responses persisted, but did not increase, after treatment withdrawal. A similar, but not statistically significant trend, was observed for HBV-specific CD4+ T cell responses. CONCLUSIONS: Decreased cccDNA transcription and low HBsAg levels are associated with HBsAg loss upon NA discontinuation in patients with HBeAg-negative CHB. The presence of functional HBV-specific T cells at baseline are associated with a successful outcome after treatment withdrawal. LAY SUMMARY: Nucleos(t)ide analogue therapy can be discontinued in a high proportion of chronic hepatitis B patients without cirrhosis. The strength of HBV-specific immune T cell responses may contribute to successful viral control after antiviral treatment interruption. Our comprehensive study provides in-depth data on virological and immunological factors than can help guide individualised therapy in patients with chronic hepatitis B.
引用
- García-López M, Lens S, Pallett LJ, et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J Hepatol. 2020. PMID: 33278456. doi:10.1016/j.jhep.2020.11.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。